Table 2.
Clinical characteristics of healthy controls and HIV-1 infected children included in the HBV vaccination study.
| Characteristic | Controls (N = 63) | HIV-1 (N = 49) |
|---|---|---|
| Age (years): Mean (Range) | 6.7 (4.0–8.0) | 7 (4.0–9.0) |
| Gender | ||
| Male | 42 (66.7%) | 25 (51.0%) |
| Female | 21 (33.3%) | 24 (49.0%) |
| MUAC | ||
| <13.5 cm | — | 5 (10.2%) |
| 13.5–14.5 cm | 5 (7.9%) | 10 (20.4%) |
| >14.5 cm | 58 (92.1%) | 34 (69.4%) |
| CD4+ T cell count (cells/μl): Mean (Range) | ND | 933.3 (195–2744) |
| WHO stage | ||
| I | NA | 27 (55.1%) |
| II | 15 (30.6%) | |
| III | 4 (8.2%) | |
| IV | 3 (6.1%) | |
| ART regimen | ||
| First line | ||
| AZT + 3TC + NVP | NA | 39 (79.6%) |
| AZT + 3TC + EFV | 3 (6.1%) | |
| ABC + 3TC + EFV | 4 (8.2%) | |
| ABC + 3TC + NVP | 1 (2.0%) | |
| Second line | ||
| ABC + ddl + LPV/r | 1 (2.0%) | |
| AZT + 3TC + LPV/r | 1 (2.0%) | |
| Months on ART: Mean (Range) | NA | 41,8 (0.03–85) |
| Months pre-ART: Mean (Range) | NA | 41.5 (2–100) |
| Viral load (Copies/ml) | ||
| <150 copies/ml | NA | 36 (73.5%) |
| 150–999 copies/ml | 4 (8.1%) | |
| 1000–57001 copies/ml | 9 (18.4%) | |
ND = not done.
NA = not applicable. MUAC = Mid-Upper Arm Circumference.